SHANGHAI - Chinese media recently reported that some drugs in hospitals are sold at 13 times their ex-factory prices, which led the National Development and Reform Commission to release new measures on drug pricing, UBS said June 23
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Plus deals involving BioCryst/Neopharmed Gentili, Sanofi/Kymera, Abion, Denovo/Chuang Yi, Carisma/OrthoCellix, Otsuka/Harbour Biomed, Aptose/Hanmi, Philochem/RayzeBio, Concentra/Elevation Oncology, and more.
Fresh from having sold Anthos to Novartis, the new CEO is expected to update the oncology and dermatology-focused firm's strategy.
Green light follows a recent rejection by the US FDA to partner Regeneron's request for an extension to the dosing interval.
